TY - JOUR
T1 - Characterization of Medication Use in a Multicenter Sample of Pediatric Inpatients with Autism Spectrum Disorder
AU - For The Autism And Developmental Disorders Inpatient Research Collaborative (Addirc)
AU - Wink, Logan K.
AU - Pedapati, Ernest V.
AU - Adams, Ryan
AU - Erickson, Craig A.
AU - Pedersen, Kahsi A.
AU - Morrow, Eric M.
AU - Kaplan, Desmond
AU - Siegel, Matthew
AU - Siegel, Matthew
AU - Erickson, Craig
AU - Gabriels, Robin L.
AU - Kaplan, Desmond
AU - Mazefsky, Carla
AU - Morrow, Eric M.
AU - Righi, Giulia
AU - Santangelo, Susan L.
AU - Wink, Logan
AU - Benevides, Jill
AU - Beresford, Carol
AU - Best, Carrie
AU - Bowen, Katie
AU - Dechant, Briar
AU - Flis, Tom
AU - Gastgeb, Holly
AU - Geer, Angela
AU - Hagopian, Louis
AU - Handen, Benjamin
AU - Klever, Adam
AU - Lubetsky, Martin
AU - MacKenzie, Kristen
AU - Meservy, Zenoa
AU - McGonigle, John
AU - McGuire, Kelly
AU - McNeil, Faith
AU - Montrenes, Joshua
AU - Palka, Tamara
AU - Pedapati, Ernest
AU - Pedersen, Kahsi A.
AU - Peura, Christine
AU - Pierri, Joseph
AU - Rogers, Christie
AU - Rossman, Brad
AU - Ruberg, Jennifer
AU - Sannar, Elise
AU - Small, Cathleen
AU - Stuckey, Nicole
AU - Tylenda, Barbara
AU - Verdi, Mary
AU - Vezzoli, Jessica
AU - Williams, Diane
N1 - Funding Information:
Funding The Autism Inpatient Collection (AIC) phenotypic database and biorepository is supported by a grant from the Simons Foundation Autism Research Initiative and the Nancy Lurie Marks Family Foundation, (SFARI #296318 to M.S.).
Funding Information:
Conflict of interest The authors report no direct conflicts of interest with this report. Dr. Wink’s current research is supported by the Si-mons Research Foundation, Autism Speaks, Riovant Sciences Ltd, and Cures Within Reach. Dr. Pedapati receives research support from the Cincinnati Children’s Hospital Research Foundation. Dr. Erickson is a consultant to and holds equity in Confluence Pharmaceuticals and is a consultant to Neurotrope and Fulcrum. Dr. Erickson is a past consultant to Alcobra Pharmaceuticals, the Roche Group, and Novartis. Dr. Erickson holds non-related IP held by CCHMC and Indiana University. Dr. Erickson receives or has received research grant support from the John Merck Fund, Indiana University School of Medicine, Cincinnati Children’s Hospital Medical Center, Autism Speaks, the United States Department of Defense, the Simons Foundation, the United States Centers for Disease Control, the National Fragile X Foundation, The Roche Group, Neuren Pharmaceuticals, the National Institutes of Health, and Riovant Sciences Ltd. Dr. Morrow is supported by the National Institute of Mental Health (R01 MH105442) and a grant from the Simons Foundation Autism Research Initiative (SFARI #286756 to EMM). Dr. Kaplan and Dr. Siegel report no conflicts of interest.
PY - 2018/11/1
Y1 - 2018/11/1
N2 - Nearly 11% of youth with Autism Spectrum Disorder (ASD) undergo psychiatric hospitalization, and 65% are treated with psychotropic medication. Here we characterize psychotropic medication usage in subjects enrolled in the Autism Inpatient Collection. Participant psychotropic medication usage rates topped 90% at admission and discharge, though there was a decline at 2-month follow-up. Antipsychotics, ADHD medications, and sleep aids were the most commonly reported classes of medications. The impact of age, gender, and non-verbal IQ on medication usage rates was minimal, though age and IQ may play a role in prescribing practices. Future work is indicated to explore medication usage trends, the impact of clinical factors on medication use rates, and the safety of psychotropic medications in youth with ASD.
AB - Nearly 11% of youth with Autism Spectrum Disorder (ASD) undergo psychiatric hospitalization, and 65% are treated with psychotropic medication. Here we characterize psychotropic medication usage in subjects enrolled in the Autism Inpatient Collection. Participant psychotropic medication usage rates topped 90% at admission and discharge, though there was a decline at 2-month follow-up. Antipsychotics, ADHD medications, and sleep aids were the most commonly reported classes of medications. The impact of age, gender, and non-verbal IQ on medication usage rates was minimal, though age and IQ may play a role in prescribing practices. Future work is indicated to explore medication usage trends, the impact of clinical factors on medication use rates, and the safety of psychotropic medications in youth with ASD.
UR - http://www.scopus.com/inward/record.url?scp=85019543395&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85019543395&partnerID=8YFLogxK
U2 - 10.1007/s10803-017-3153-x
DO - 10.1007/s10803-017-3153-x
M3 - Article
C2 - 28516426
AN - SCOPUS:85019543395
VL - 48
SP - 3711
EP - 3719
JO - Journal of Autism and Developmental Disorders
JF - Journal of Autism and Developmental Disorders
SN - 0162-3257
IS - 11
ER -